stemcell technologies
glassdoor has 98 stemcell technologies reviews submitted anonymously by stemcell technologies employees. read employee reviews and ratings on glassdoor to decide if stemcell technologies is right for you .
stemcell technologies develops cell culture media, cell separation products and ancillary reagents for immunology and hematology research fields stemcell technologies was founded in 1993. stemcell technologies' headquarters is located in vancouver, br ...
owler has collected 13 screenshots of stemcell technologies' website since may 2014. the latest stemcell technologies website design screenshot was captured in sep 2017 .
stemcell technologies' s president & ceo, allen eaves, currently has an approval rating of 69% . stemcell technologies' s primary competitors are
19 stemcell technologies inside sales representative jobs, including salaries, reviews, and other job information posted anonymously by stemcell technologies inside sales representative employees. find stemcell technologies inside sales representative jobs on glassdoor. get hired. love your job .
stemcell technologies develops cell culture media, cell separation products and ancillary reagents for immunology and hematology research fields stemcell technologies is headquartered in vancouver, british columbia. allen eaves is the president & ceo of stemcell technologies. stemcell technologies' s main competitors are miltenyi biotec, lonza and biological industries. as of june 2018, stemcell technologies has 31. 8k fans on facebook and 12. 8k followers on twitter .
mammocult™ human medium for culture of mammospheres and tumorspheres from stemcell technologies inc. | selectscience
stemcell technologies is a canadian biotechnology company that develops specialty cell culture media ...
glassdoor gives you an inside look at what it' s like to work at stemcell technologies, including salaries, reviews, office photos, and more. this is the stemcell technologies company profile. all content is posted anonymously by employees working at stemcell technologies .
stemcell technologies currently has 12, 756 followers on twitter. as of july 2014 stemcell technologies had 6, 733 followers. that' s a 89 percent increase in 3 years
stemcell technologies currently has 31, 771 fans on facebook. as of july 2014 stemcell technologies had 13, 048 fans. that' s a 143 percent increase in 4 years
dr. allen eaves of stemcell technologies inc. named ey entrepreneur of the year™ pacific 2016
there are no threads in stemcell technologies inc. sepmate reviews at this time. add a review
stemcell technologies inc. sam lloyd - burton, phd, senior product marketing manager 604. 675. 7888
dr. allen eaves of stemcell technologies inc. named ey entrepreneur of the year™ pacific 2016 - ey - canada
lonza is a top competitor of stemcell technologies. lonza was founded in 1897, and its headquarters is in basel, basel - city. lonza competes in the biotechnology industry. lonza has 8, 809 more employees than stemcell technologies .
biological industries is stemcell technologies' s # 3 rival. biological industries was founded in cromwell, connecticut } in 1982. biological industries is in the biotechnology field. compared to stemcell technologies, biological industries generates $ 65. 6m more revenue .
stemcell technologies has employees and is the second highest among it' s top 10 competitors. the top 10 competitors average 280 .
stemcell technologies inc. is a leader in the development of specialty cell culture media, cell isolation products and ancillary reagents for life science research. driven by science and a passion for quality, stemcell technologies provides over 1500 products to more than 70 countries worldwide. urltoken
stemcell technologies inc is a privately - owned biotechnology company that develops specialty cell culture media, cell separation products and ancillary ...
this video is an overview of stemcell technologies inc. which is a privately - owned biotechnology company that develops specialty cell ...
stemcell technologies' s revenue is the third highest among it' s top 10 competitors. the top 10 competitors average $ 39m .
stemcell technologies inc. is a privately - owned biotechnology company based in vancouver that helps power leading - edge life science research around the world .
miltenyi biotec is seen as one of stemcell technologies' s top competitors. miltenyi biotec was founded in 1989, and is headquartered in bergisch gladbach, north rhine - westphalia. miltenyi biotec operates in the biotechnology industry. miltenyi biotec generates $ 217. 5m more revenue vs. stemcell technologies .
as scientists helping scientists, stemcell technologies inc. is committed to providing high - quality cell culture media, cell isolation products and accessory reagents for life science research. driven by science and a passion for quality, stemcell technologies provides over 2000 products to more than 70 countries worldwide. stemcell technologies’ specialty cell culture reagents, instruments and tools are designed to support science along the basic to translational research continuum. to learn more, visit urltoken .
i applied through an employee referral. the process took 3 weeks. i interviewed at stemcell technologies (vancouver, bc) in january - 2018 .
how much do stemcell technologies employees make? glassdoor has salaries, wages, tips, bonuses, and hourly pay based upon employee reports and estimates .
they are robust, proven technologies that we can deploy with absolute confidence .
copyright © 2018 by stemcell technologies inc. all rights reserved including graphics and images. stemcell technologies & design, stemcell shield design, scientists helping scientists, aggrewell, celladhere, clonacell, easyplate, easysep, endocult, epicult, escult, erythroclear, fresr, mammocult, megacult, mesencult, methocult, myelocult, neurocult, pneumacult, prostacult, relesr, robosep, rosettesep, sepmate, smartdish, spinsep, stemdiff, stemsep, stemspan, and stemvision are trademarks of stemcell technologies canada inc. all other trademarks and registered trademarks are the property of their respective holders. while stemcell has made all reasonable efforts to ensure that the information provided by stemcell and its suppliers is correct, it makes no warranties or representations as to the accuracy or completeness of such information .
join our talent network and get stemcell news and job alerts delivered to your inbox .
london, ontario, aug. 26, 2015 (globe newswire) - - lawson health research institute (lawson) and stemcell technologies inc. announced today that they have signed a license agreement giving stemcell global exclusive rights to commercialize novel tools for parkinson’s disease research .
allen eaves stemcell technologies | vancouver, british columbia urltoken a privately - owned biotechnology company that develops speciality cell culture media, cell separation products and ancillary reagents for life science research .
the top 10 competitors in stemcell technologies' competitive set are miltenyi biotec, lonza, biological industries, axol bioscience, biolegend, life technologies, wuxi apptec, ebioscience, novasep and peprotech. together they have raised over 3. 5b between their estimated 24. 4k employees .
through our three business units: stemcell technologies inc. , malachite management inc. and stemsoft software inc. , we offer exciting careers in 30 departments in our offices around the globe .
stemcell technologies inc. ’s quality management system is certified to iso 13485. products are for research use only and not intended for human or animal diagnostic or therapeutic uses unless otherwise stated .
editor' s note: industry association lifesciences bc also recently announced stemcell technologies inc. as its life sciences company of the year at the recent 2015 lifesciences bc awards held earlier this year .
this video is an overview of stemcell technologies inc. which is a privately - owned biotechnology company that develops specialty cell culture media, cell separation products and accessory reagents for life science research .
“we are delighted for the opportunity to bring these important products to the research community and we are excited to be the exclusive supplier. ” - dr. allen eaves, ceo and president of stemcell technologies
the seeds for stemcell technologies were planted in 1981 at the terry fox laboratories at the university of british columbia. eaves was unsatisfied with the tools available to him for his cancer research and his team started creating their own blood stem cell culture media. within twelve years, the demand for his products was so great, eaves launched stemcell technologies. since then, it has become the largest biotech company in canada .
stemcell technologies inc. is a canadian biotechnology company that develops specialty cell culture media, cell isolation systems and accessory products for life science research. driven by science and a passion for quality, stemcell supports the advancement of scientific research around the world with our catalogue of more than 2000 cell biology research tools .
as scientists helping scientists, stemcell technologies is committed to providing high - quality cell culture media, cell isolation products and accessory reagents for life science research. driven by science and a passion for quality, stemcell technologies provides over 2000 products to more than 70 countries worldwide. our specialty cell culture reagents, instruments and tools are designed to support science along the basic to translational research continuum. to learn more, visit urltoken
“lawson’s partnership with stemcell technologies is critically important to provide global access to these novel research tools that are anticipated to enable unique insights into the disease process. ” - kirk brown, manager, business development, lawson
the stem cell company accellta announced today that it has granted exclusive worldwide rights to stemcell technologies inc. for manufacturing and distribution of medium for culturing pluripotent stem cells in suspension under feeder - free, non - adherent conditions .
brainphys™ neuronal medium will complement stemcell’s extensive portfolio of products for neural cell culture applications, including the neurocult™ product line for tissue - derived neural cells, and the stemdiff™ neural system for hpsc - derived neural cells. this project will leverage stemcell technologies’ extensive experience in developing and commercializing specialized culture media for life science research. the commercial brainphys™ neuronal medium will be developed and manufactured using stemcell technologies’ rigorous raw material screening and quality control processes. this will ensure that the final product is of the highest quality, with maximal performance and minimal lot - to - lot variability .
stemcell provides high quality, standardized, reproducible reagents that work the way researchers want them to work .
“over the past 20 years, stemcell technologies has grown remarkably to become an established global biotech life sciences leader. stemcell is a significant canadian biotech success story as evidenced by cumulative sales over $ 550 million, 95% of which is derived from exports, $ 70 million in r & d investment and the employment of over 600 canadians, ”
stemcell technologies inc. is a privately - owned biotechnology company based in vancouver that helps power leading - edge life science research around the world. scientists performing stem cell, immunology, cancer, regenerative medicine and cellular therapy research are among those ...
( vancouver, 1 october 2016) dr. allen eaves, chairman, president and chief executive officer of stemcell technologies, a global biotechnology company that supplies tools and services to enable life science research, is this year’s entrepreneur of the year pacific winner .
stemcell ceo and founder dr. allen eaves started with a passion for science and a staff of eight. today, stemcell is canada’s largest biotechnology employer and has more than 1000 employees in 11 countries around the world. explore our history and our culture .
“lawson is very pleased to partner with stemcell technologies to make these products available to all researchers, with the immediate goal of moving parkinson’s disease research forward and the ultimate goal that it will lead to better treatment options for patients. ” - dr. david hill, scientific director, lawson
explore the exciting career paths at stemcell. we offer competitive benefits and opportunities to achieve your full potential with growth - driven training and development .
stemcell has a great corporate culture. wonderful people, management, training, opportunities for growth, and opportunities for fun. high value on teamwork and collaboration across the company, and many ways to meet and interact with colleagues. it is fast pace and rewarding to work with stemcell .
explore the exciting career paths at stemcell, which include competitive benefits and opportunities to achieve your full potential with growth - driven training and development .
a team led by dr. matthew hebb, a neurosurgeon - researcher at lawson and western university’s department of clinical neurological sciences has been developing innovative strategies to study parkinson’s disease. “the partnership with stemcell technologies greatly expands the expertise focused on moving this technology forward and providing critical access to researchers worldwide. ” says dr. hebb .
“mtesr™1 is proving to be a very versatile tool for working with ipscs, ” said dr. clive glover, senior product manager at stemcell technologies. “previously, it has been shown that ipscs can be expanded routinely with mtesr™1, but this study suggests that mtesr™1 can be used all the way from initial derivation through to expansion. ”
so that’s the niche that stemcell technologies resides in. it’s really helping researchers do their research better by providing standardized, high quality tools. i jokingly say we provide the picks and shovels for the stem cell gold rush. we’re not trying to find the gold; we just provide the tools that will help scientists make those discoveries .
dr allen eaves founded the terry fox laboratory for haematology and oncology research with his wife dr connie eaves and was the lab’s director for 25 years, from 1981 to 2006. he was also professor and head of clinical haematology at the university of british columbia for 18 years. he is now founder, president and ceo of stemcell technologies inc .
we all begin our lives curious about the world around us, the way it works and our place in it. at stemcell technologies, we never lose that curiosity. it inspires and motivates us to discover and innovate. it drives us to develop technologies, create products, and offer services that will help scientists around the world do research that progresses scientific knowledge and supports breakthroughs. in the field of biotechnology, there is no better company in which to find inspiration, fulfill your potential and define your success with like - minded people .
, accellta' s chairman and ceo, said :
enabling large - scale production and reducing the costs of stem cell products are the key technological challenges the stem cell industry is facing today, and some of the main goals of accellta' s revolutionary technologies. we are delighted to partner with stemcell technologies, a global leader in stem cell culture solutions, and believe this partnership will maximize the global reach of our solutions and make a significant impact on the large - scale use, applicability and affordability of stem cell - based products
.
in addition to tesr™ maintenance media, stemcell technologies has developed tesr™ - based media to support other facets of the pluripotent stem cell research workflow, including media optimized for reprogramming fibroblasts (tesr™ - e7™), reprogramming blood cell types and fibroblasts (reprotesr™), differentiation (tesr™ - e6 and tesr™ - e5) and cryopreservation (mfresr™ and fresr™ - s) .
commenting on the agreement, dr. allen eaves, ceo and president of stemcell technologies stated: “we are delighted to have entered into an agreement with the salk institute to make this novel technology accessible to researchers around the world, and are confident that this important invention will accelerate neuroscience research, improve our understanding of neurological diseases and facilitate the development of novel drug formulations. ”
since 1993, the company has grown 20% each year and now has more than 800 employees and 2000 cell biology research tools. furthermore, stemcell technologies continues to reinvest all its profits into developing products for the international research community. their commitment to the scientific community allows them to provide educational opportunities, webinars and workshops to keep researchers up - to - date with developments in their fields .
mammocult™ human medium for culture of mammospheres and tumorspheres - culture human mammospheres from primary tissues and tumorspheres from breast cancer cell lines. mammocult™ human medium for culture of mammospheres and tumorspheres from stemcell technologies is recommended for: • culture of primary human mammary epithelial cells in suspension as mammospheres • culture of human breast cancer cell lines as tumorspheres • maintain and sustain mammospheres and tumorspheres • expansion of mammos... read more
stemcell is growing fast, and we' re always looking for smart, motivated people to join our team. stemcell is the largest biotechnology employer in canada, and is proud to have been named company of the year by biotecanada and life sciences company of the year by life sciences bc in 2015, as well as having received three bc export awards in 2016, including exporter of the year !
“importantly, stemcell' s demonstrated commitment to employing canadian science graduates contributes significantly to keeping canadian scientists in this country and growing our scientific research capacity which greatly enhances the health of the canadian biotech ecosystem. ”
aldefluor® reagent system - for the identification, evaluation and isolation of stem and progenitor cells expressing high levels of aldh. the aldefluor® reagent system from stemcell technologies offers a novel approach to the identification and isolation of stem / progenitor cells based on aldh (aldehyde dehydrogenase) activity, rather than cell surface phenotype. while aldefluor® is optimized for use with human hematopoietic cells, it has also been adapted for use with other species and cell ty... read more
i love working for stemcell. this company has a ton of integrity, and truly cares about helping scientists. with fast growth there is always lots to do, and i always feel i' m making a meaningful contribution .
stemcell is guided by our love of science and our passion for quality. our company values of innovation, quality, integrity, collaboration and responsiveness drive our unrelenting pursuit of scientific knowledge. we stand by our customers to provide outstanding products, technical support and training .
accellta is currently focused on creating strategic partnerships with biopharma and stem cell companies for developing large - scale and cost - effective manufacturing processes for cell products. in the future the company is aimed at expanding the use of its technologies for in vitro toxicology studies and potential therapeutic applications of stem cells .
eventually the demand for the media from researchers around the world warranted building a designated clean room for production. the tfl did not have the funding and instead, eaves was encouraged to purchase the business and create an independent company. mortgaging his house and receiving a loan from western economic diversification, eaves was able to build a clean room and stemcell technologies inc. was born on july 2, 1993. stemcell has become the largest biotech company in canada and continues to reinvest all profits back into developing products to better support the international research community. as of 2017, the company employs more than 1000 people globally, with over one - third of those holding a phd or msc, and the majority of employees having a bsc or engineering degree. a large number of the company’s employees are located in vancouver, canada with additional employees and facilities in 11 other countries .
the novel medium represents a breakthrough in stem cell manufacturing technologies; it was designed by accellta to dramatically reduce the cost and duration of pluripotent stem cell production by enabling mass culturing of cells in suspension, using a bioreactor free of micro - carriers or any other adherence surfaces, which replaces the use of numerous culture dishes or micro - carriers .
stemcell technologies was launched in 1993 when founder and ceo allen eaves needed a way to meet the increasing demands for his standardized, cost - effective cell culture media for growing blood - forming stem cells. at the time, eaves was a hematologist and cancer researcher heading the terry fox laboratories (tfl) and head of clinical hematology at the university of british columbia in vancouver, canada. unsatisfied with commercially available cell culture reagents, eaves’ research group at the tfl began making their own hematopoietic stem cell culture media using the highest quality materials they could find. colleagues also wanted to use this media, and eaves was able to supplement his research funds by selling culture media to other lab groups .
stemcell specializes in developing cell culture media, cell separation systems, instruments and other reagents for use in life sciences research across the basic to translational research continuum. our products are designed and developed by highly trained, world class scientists to streamline research protocols, reduce experimental variability, and increase the accuracy of results. we develop our product lines to support entire experimental workflows, from cell isolation through characterization, expansion, differentiation, maintenance and storage, and are always looking for ways to further support our customers through training, knowledge and new products. stemcell’s research and development team often collaborates with academic partners to develop, produce and distribute products specific to a given research field .
for more information, please contact: lawson - laura goncalves communications & external relations t: 519 - 685 - 8500 ext. 64059 c: 226 - 448 - 1525 laura. goncalves @ urltoken urltoken stemcell – lubametlitskaia, msc. director, licensing and business development e - mail: bdv @ urltoken visit us at: www. urltoken
stemcell brings together a highly skilled and dynamic group. as a company of scientists helping scientists, the majority of our 900 - person team has a science degree, with more than one - third of employees holding an msc or a phd. we also employ engineers, mbas, cpas, and other professionals in a variety of departments .
in addition to expanding our original line of hematology products, we have grown our product portfolio to include a comprehensive suite of immune cell isolation tools as well as products that support research using pluripotent stem cells and mesenchymal stem cells. we have also developed suites of products optimized for neural, mammary, prostate, pulmonary, pancreatic, and intestinal cell biology research. additionally, stemcell’s contract assay services department supports researchers by developing tailor - made in vitro assays customized for their research needs. finally, by offering accessory components such as primary cells, antibodies and cytokines, as well as labware and instruments via our bioengineering division, stemcell provides scientists with all of the tools necessary to carry out their research .
we know that effective training, communication and collaboration is essential for science to happen. as a company, stemcell is deeply rooted in the scientific community and science education, and these values drive an ongoing effort to provide scientists with the resources that they need to keep current with the latest scientific advances and innovations in their fields. for example, our education team provides hands - on training courses and workshops as well as proficiency testing for assay standardization and custom on - site education courses. we also produce professional quality videos that provide product support and education, as well as host webinars with field experts and offer free wallcharts, technical bulletins, blogs, newsletters and other communications resources to support the exchange of scientific knowledge and keep researchers informed about tools, tips and technologies in their fields .
accellta develops, manufactures and markets a range of revolutionary solutions for better affordability and quality of stem cell culturing and for developing specialty cell culture tools, services and cell lines. accellta' s technologies are the result of over 15 years of pioneering research and development at the stem cell center in the technion' s rappaport faculty of medicine. accellta operates a state - of - the - art manufacturing facility, laboratories and offices in
stemcell also offers a large range of career opportunities for people with scientific training and expertise, but who are looking for a career away from the bench. roles in sales, product management, science communications & marketing, technical support, business development & licensing, business operations, quality assurance and regulatory affairs require a combination of science expertise and business acumen and provide exciting career opportunities for scientists outside of the lab .
“allen’s accomplishments as an entrepreneur and a scientist are incredible, ” says lui petrollini, entrepreneur of the year pacific program director. “most people look to slow down their life in retirement, but allen has done the opposite. he used his experience to focus on creating products and services he developed while doing his scientific research. as a result, stemcell’s strides in the biotechnology industry are having a global impact. ”
in sales, we build relationships with scientists in the field as we help them identify effective, efficient and innovative ways to approach their research. our global team shares an impressive array of scientific and sales backgrounds. we collaborate and support one another to keep current with the latest advances and technologies in the fields that we support, and to achieve consistent growth for the company. having the opportunity to interact with brilliant scientists every day is both exhilarating and humbling, and makes for an incredibly rewarding career .
have you left your academic roots completely behind you? no, definitely not. the money we made when we started the company was used to support our research in the terry fox lab, and it still is to a certain extent. five years ago i had to retire from the university when i reached 65 so i’ve been working in the company pretty well full time since then. i’d done various different things in the academic environment and i was feeling pretty good about life in general so this was something different to do when i retired. but at stemcell technologies we’re very keen to not get too big too fast and to work closely with our research colleagues in academia and in industry to carefully fulfill their needs for high quality reagents and instruments. i run the company sort of like a graduate school with lots of creative young scientists doing neat things; the idea is to have lots of people in the company who are really knowledgeable about what they’re doing and yet still remain in touch with research .
stemcell is a company of scientists helping scientists. many of our team members have an msc or phd and others simply share a passion for science and its ability to make a real difference in the world. a culture of curiosity, collaboration, and innovation pulses throughout the company. it is inspiring to work with such a fantastic group united by a common goal – to help progress the pursuit of scientific knowledge. our great leadership team, rapid growth, and extensive internal training programs create fantastic opportunities for career growth and personal development .
in research & development, and throughout stemcell, there is a shared drive to develop products that help researchers advance science. we bring together our internal scientific expertise and our intimate understanding of the fields we support, inventing ways to help leading scientists do their work more efficiently and effectively. this can be an incredibly fun and creative pursuit, as well as intensely challenging and complex. seeing the end result - when a technology comes to life, and scientists around the world adopt it into their research - brings an amazing sense of pride, comradery and accomplishment .
sepmate™ is manufactured following current good manufacturing practices (cgmp) and tubes are sterilized by irradiation. sepmate™ is registered as an in vitro diagnostic (ivd) device in australia, canada, europe and the united states for the isolation of mononuclear cells from whole blood or bone marrow by density gradient centrifugation. in china sepmate™ is considered a non - medical device by the china food and drug administration (cfda), and should therefore be used as general laboratory equipment. the end user is responsible for determining whether the product is suitable for their specific application. in regions outside of australia, canada, china, europe and the united states sepmate™ is available as a research use only (ruo) product. stemcell operates a quality management system which complies with the requirements of iso 13485: 2003 .
why does stem cell research need companies? what role do companies play? there is no question that for stemcell technologies the role is to provide high quality, standardized, reproducible reagents that just work every time, the way we say they are going to work and the way researchers want them to work. and that of course saves researchers a whole lot of time – they don’t have to make up the mixtures for growing their cells from scratch. years ago, the students or post - doctoral researchers in a lab had to make up all the different solutions and growth media the lab needed. invariably someone would make a mistake and there wasn’t the quality control that goes into all our reagents now. we screen and test very carefully all the raw materials that go into our products, and then once they’re made we re - test and re - screen them very rigorously to make sure they meet our standards. that just can’t happen in a single lab because researchers don’t have the resources, time or even the skills to do all those tests on a routine basis for all the reagents they use. culture media have got pretty sophisticated so it is now quite a serious thing to put them together properly with all the different components they contain. buying reagents that are already validated to do what they’re supposed to do is really a great saving for researchers. not everybody sees it that way because they think they can do it themselves and make the reagents cheaper. that’s true, they often can, but a small mistake can ruin an experiment that maybe takes a month or two before you get the result. so then you’ve lost a whole lot of time and that’s a very costly thing to have happen in your lab .
expansion of cd34 + cells normalized relative to the values obtained in sfem medium (dark gray bar) after culturing purified cd34 + cb cells for 7 days in stemspan™ sfem, sfem ii (gold bar) and acf (orange bar), and six media from other suppliers (light gray bars; competitor 1 - 6, which included, in random order, stemline ii (sigma), hpgm (lonza), hp01 (macopharma), scgm (cellgenix), stempro34 (life technologies) and x - vivo - 15 (lonza) ). all media were supplemented with the stemspan™ cd34 + expansion supplement. vertical lines indicate 95% confidence limits, the range within which 95% of results fall. the numbers of cells produced in stemspan™ sfem ii were significantly higher than in all other media (* p < 0. 01, paired t - test, n = 6) .
the numbers of erythroid cells, normalized relative to the values obtained in stemspan™ sfem medium (dark gray bar), obtained after culturing purified cd34 + cb cells for 14 days in stemspan™ sfem, sfem ii (gold bar) and acf (orange bar), and six media from other commercial suppliers (light gray bars; competitor 1 - 6, which included, in random order, stemline ii (sigma), hpgm (lonza), hp01 (macopharma), scgm (cellgenix), stempro34 (life technologies) and x - vivo - 15 (lonza) ). all media were supplemented with stemspan™ erythroid expansion supplement. vertical lines indicate 95% confidence limits, the range within which 95% of results fall. the numbers of cells produced in stemspan™ sfem ii were significantly higher than in all other media (* p < 0. 05, paired t - test, n = 6) .
the numbers of megakaryocytes, normalized relative to the values obtained in stemspan™ sfem medium (dark gray bar), obtained after culturing purified cd34 + cb cells for 14 days in stemspan™ sfem, sfem ii (gold bar) and acf (orange bar), and six media from other commercial suppliers (light gray bars; competitor 1 - 6, which included, in random order, stemline ii (sigma), hpgm (lonza), hp01 (macopharma), scgm (cellgenix), stempro34 (life technologies) and x - vivo - 15 (lonza) ). all media were supplemented with stemspan™ megakaryocyte expansion supplement (catalog # 02696). vertical lines indicate 95% confidence limits, the range within which 95% of results fall. the numbers of cells produced in the stemspan™ media were significantly higher than in the other media (* p < 0. 01 paired t - test, n = 6) .
expansion of cd34 + cells normalized relative to the values obtained in stemspan™ sfem medium (dark gray bar) after culturing purified cd34 + cb cells for 7 days in stemspan™ sfem, sfem ii (gold bar) and acf (orange bar), and six media from other commercial suppliers (light gray bars; competitor 1 - 6, which included, in random order, stemline ii (sigma), hpgm (lonza), hp01 (macopharma), scgm (cellgenix), stempro34 (life technologies) and x - vivo - 15 (lonza) ). all media were supplemented with stemspan™ cc100 cytokine cocktail. vertical lines indicate 95% confidence limits, the range within which 95% of results fall. the numbers of cells produced in stemspan™ sfem ii were significantly higher than in all other media, except the numbers of cb cells produced in stemspan™ - acf (* p < 0. 05, paired t - test, n = 6) .
brainphys™ medium, described in a recent publication in the proceedings of the national academy of sciences (c. bardy et al. , epub ahead of print), was invented by cedric bardy in the lab of renowned neuroscientist fred h. gage. classical culture media used for neuronal culture applications were found to impair action potential generation and synaptic communication. in order to improve the physiological relevance of neuronal culture conditions, bardy et al. developed brainphys™ medium to better represent the environment experienced by neurons in the human brain .
this formulation promotes optimal neuronal and synaptic activity while supporting long - term culture of both human pluripotent stem cell (hpsc) - derived neurons and primary tissue - derived neurons. according to bardy et al. , “the improvements made in this medium reduce the gap between in vivo brain physiological conditions and neuronal models in vitro. ” it is hoped that increasing the physiological relevance of in vitro neuroscience research will improve the probability of successful translation of scientific discoveries from the laboratory to the clinic .
“our goal was to develop a culture condition that would support both healthy neuronal circuits and let us monitor the functional properties of mature neurons, without having to switch to different media, ” says bardy .
specifically, we reasoned that such cell media should allow for optimal physiological neuronal activity. after sharing our work with our colleagues, we wanted to make this neuronal medium easily available to the scientific community. ”
the salk institute for biological studies is one of the world' s preeminent basic research institutions, where internationally renowned faculty probes fundamental life science questions in a unique, collaborative and creative environment. focused both on discovery and on mentoring future generations of researchers, salk scientists make groundbreaking contributions to our understanding of cancer, aging, alzheimer' s, diabetes and infectious diseases by studying neuroscience, genetics, cell and plant biology, and related disciplines. faculty achievements have been recognized with numerous honors, including nobel prizes and memberships in the national academy of sciences. founded in 1960 by polio vaccine pioneer jonas salk, md. , the institute is an independent nonprofit organization and architectural landmark .
this site uses cookies. by continuing to browse this business wire site (and / or any other business wire website), you accept the use of cookies .
simply incubate your sample with the appropriate rosettesep™ antibody cocktail for 20 minutes at room temperature, and then perform a standard density gradient centrifugation (e. g. ficoll™). the tetrameric antibody complexes (tac) in the rosettesep™ cocktail crosslink unwanted cells to red blood cells in the sample to form immunorosettes .
these immunorosettes pellet during density gradient centrifugation, leaving untouched, highly purified cells at the interface between the plasma and the density gradient medium .
eric weddle jersey greg olsen jersey jay cutler jersey dez bryant jersey demaryius thomas jersey golden tate iii jersey david bakhtiari jersey j. j. watt jersey
html public
- / / w3c / / dtd xhtml 1. 0 strict / / en
urltoken
latest: spanish hospital uses syngene system for western blot imaging to speed up clinical ...
evaluation of micro - pillar array columns combined with high - resolution mass spectrometry for ...
taking flow to the next level: a novel, integrated platform to accelerate ...
automated low - volume liquid handling for cost - effective ngs library ...
will have to fight to move it or get another when lab moves. great investment .
it is really easy to use, very reliable, a must have for high throughput experiments .
aldefluor® reagent system - for the identification, evaluation and isolation of stem and progenitor cells expressing high levels of aldh .
in a landmark paper, researchers at stanford university have described a new way to derive human induced pluripotent stem cells (ipscs) without the use of contaminating mouse feeder cells. using adipose cells as the starting cell population and mtesr™1, a defined medium that allows the expansion of human embryonic and induced pluripotent stem cells without the use of feeders, the researchers were able to fully reprogram the cells to the pluripotent state .
ipscs could potentially become the source of patient specific replacement cells, but methods used to generate these cells to date have relied on the use of mouse feeder cells which make the cells unsuitable for clinical use .
the fact that adipose cells can now be reprogrammed without the use of contaminating feeder cells means we are one step closer to being able to use these cells in the clinic ,
said dr. joseph wu, assistant professor of medicine and radiology at stanford university and senior author on the publication .
mtesr™1 is a fully defined medium and is the most widely used feeder - independent method for culturing human pluripotent stem cells, with citations in more than 25 publications .
the opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of news - medical. net .
at st. john' s, we are building an innovation center in pharmaceutical technology. we are involved with double upping new drug delivery systems, as well as a new processing agreement. in addition, we are focussing on personalized medications .
with the advent of artificial intelligence, it is imperative that we examine the ethics of machine learning and data collection. hugh whittall, director of the nuffield council on bioethics, explains what ai is, how it is transforming the healthcare industry and the ethical concerns of the council .
dr. jagadeesh bayry from inserm discusses his recent research in the field of immunology, and how t regulatory cells activate, rather than suppress, basophils .
news - medical. net provides this medical information service in accordance with these terms and conditions. please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician / doctor and the medical advice they may provide .
this site complies with the honcode standard for trustworthy health information: verify here .
by continuing to browse or by clicking
accept all cookies ,
you agree to the storing of first and third - party cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. find out more .
endif ] - - > < script type =
text / javascript
> / / <! [ cdata [ mage. cookies. path =' /'; mage. cookies. domain =' urltoken'; / / ]
javascript seems to be disabled in your browser. you must have javascript enabled in your browser to utilize the functionality of this website .
. neurocult™ allows researchers to standardize their culture system and minimize variability, leading to increased reproducibility among experiments .
comprehensive. media, supplements and accessory reagents are available for primary neurons and neural stem / progenitor cells from human, mouse and rat tissues .
complete workflow. isolate, expand, and differentiate mouse and rat neural stem and progenitor cells from normal and tumor tissues .
versatile. culture and expand human neural stem cells and brain tumor stem cells in a serum - free and / or xeno - free system .
reliable. rigorous raw material screening and quality control ensure minimal lot - to - lot variability .
also available: neurocult™ sm1 without vitamin a * see also: stemdiff™ neuron differentiation kit and stemdiff™ neuron maturation kit .
defined and serum - free basal medium and supplement brainphys™ neuronal medium is based on the formulation invented by cedric bardy and fred h. gage 2
kit includes brainphys™ neuronal medium and neurocult™ sm1 neuronal supplement * see also: stemdiff™ neuron differentiation kit and stemdiff™ neuron maturation kit .
brewer gj et al. (1993) optimized survival of hippocampal neurons in b27 - supplemented neurobasal, a new serum - free medium combination. j neurosci res. 35 (5): 567 - 76 .
bardy c et al. (2015) neuronal medium that supports basic synaptic functions and activity of human neurons in vitro. proc natl acad sci 112 (20) e2725 - e2734 .
mammocult™ human medium for culture of mammospheres and tumorspheres - culture human mammospheres from primary tissues and tumorspheres from breast cancer cell lines .
, and other cell types using the clonacell™ portfolio of innovative cell line - specific media, designed to provide optimal culture conditions. available in both methylcellulose - based (semi - solid) and liquid form ,
formulations help you achieve a high probability of monoclonality and clonal diversity in just one step .
research - stage biotechnology companies and antibodies service companies use clonacell™ - hy to complete antibody development projects faster and deliver the best antibodies for each application .
dr. m. javad aman, president and cso, integrated biotherapeutics, inc .
simple and convenient. save time with semi - solid cloning. don’t waste resources on empty cloning wells .
proven. superior cloning efficiency and growth of cho and other cell lines, hybridomas and myelomas .
versatile. base methylcellulose medium is easily customized for your cell type. custom formulations, packaging, and additional sizes are available upon request .
chronopoulou e et al. (2014) hybridoma technology for the generation of rodent mabs via classical fusion. in: ossipow v, n fischer (eds .) monoclonal antibodies: methods and protocols, methods in molecular biology. 2nd ed. new york: springer science + business media. : pp47–70. cesaro a et al. (2012) an inflammation loop orchestrated by s100a9 and calprotectin is critical for development of arthritis. plos one 7 (9): e45478. smith s a. et al. (2012) persistence of circulating memory b cell clones with potential for dengue virus disease enhancement for decades following infection. j virol 86 (5): 2665–2675. fang l et al. (2008) essential role of tnf receptor superfamily 25 (tnfrsf25) in the development of allergic lung inflammation. j exp med 205 (5): 1037–1048. ulbrandt nd et al. (2006) isolation and characterization of monoclonal antibodies which neutralize human metapneumovirus in vitro and in vivo. j virol 80 (16): 7799–7806. grimaldi jc et al. (1999) depletion of eosinophils in mice through the use of antibodies specific for c - c chemokine receptor 3 (ccr3). j leukoc biol 65 (6): 846–853 .
cabral tm et al. (2014) development of neutralizing monoclonal antibodies against the pandemic h1n1 virus (2009) using plasmid dna immunogen. j virol methods 195: 54–62. retamal m et al. (2014) epitope mapping of the 2009 pandemic and the a / brisbane / 59 / 2007 seasonal (h1n1) influenza virus haemagglutinins using mabs and escape mutants. j gen virol 95 (pt _ 11): 2377–2389. hostetter dr et al. (2007) hip is a pro - survival substrate of granzyme b. j biol chem 282 (38): 27865–27874. jin c et al. (2006) immunoglobulin g specifically binding plant n - glycans with high affinity could be generated in rabbits but not in mice. glycobiology 16 (4): 349–357. kuroki m et al. (2005) preparation of human igg and igm monoclonal antibodies for mk - 1 / ep - cam by using human immunoglobulin gene - transferred mouse and gene cloning of their variable regions. anticancer res 25 (6a): 3733–3739 .
flyak ai et al. (2015) mechanism of human antibody - mediated neutralization of marburg virus. cell 160 (5): 893–903. fang l et al. (2008) essential role of tnf receptor superfamily 25 (tnfrsf25) in the development of allergic lung inflammation. j exp med 205 (5): 1037–1048. matsumoto sc et al. (2006) retinal dysfunction in patients with chronic chagas’ disease is associated to anti - trypanosoma cruzi antibodies that cross - react with rhodopsin. faseb j 21: 1–21 .
chen d et al. (2014) increased expression of id1 and id3 promotes tumorigenicity by enhancing angiogenesis and suppressing apoptosis in small cell lung cancer. genes cancer 5 - 6 (may): 212–225. stern hm et al. (2010) development of immunohistochemistry assays to assess galnt14 and fut3 / 6 in clinical trials of dulanermin and drozitumab. clin cancer res 16 (5): 1587–1596. chen y et al. (2007) armed antibodies targeting the mucin repeats of the ovarian cancer antigen, muc16, are highly efficacious in animal tumor models. cancer res 67 (10): 4924–4932. wittman vp et al. (2006) antibody targeting to a class i mhc - peptide epitope promotes tumor cell death. j immunol 177 (6): 4187–4195 .
megacult™ - c is a collagen - based culture system for colony - forming unit (cfu) assays of megakaryocyte progenitors (cfu - mk) from human or mouse hematopoietic tissues. 1 megakaryocyte colonies are difficult to detect by morphological criteria alone as colonies may contain as few as three cells and megakaryocytes cannot be easily distinguished morphologically from other cell lineages, particularly macrophages. unlike methylcellulose - based media used in cfu assays for other lineages, collagen gels used in megacult™ can be readily dehydrated for subsequent cytochemical or immunocytochemical staining. human cfu - mk colony detection in megacult™ is based on immunocytochemical staining for the megakaryocyte marker cd41, while mouse colony detection is based on acetylcholinesterase activity .
megacult™ medium is available in formats with or without cytokines or added lipids. megacult™ media with cytokines contain recombinant human (rh) il - 3, il - 6 and tpo for optimal growth of human cfu - mk. megacult™ media without cytokines is recommended for applications where control over the types and amounts of cytokines to use is important, for example for investigation of factors influencing the growth and maturation of megakaryocytic progenitor cells. megacult™ - c media without cytokines is also used for the culture and enumeration of mouse cfu - mk after addition of appropriate cytokines, such as recombinant mouse il - 3, rhil - 6, rhil - 11, rhtpo and / or other factors, chosen by the user .
culture and enumeration of megakaryocytic progenitors in cfu - mk assays on human cord blood, bone marrow and peripheral blood .
cfu - mk assays on human cord blood, bone marrow and peripheral blood .
cfu - mk assays on mouse bone marrow. the addition of cytokines is required .
cfu - mk assays on progenitor - enriched preparations of human cord blood, bone marrow and peripheral blood. the addition of cytokines is required .
cfu assays for other progenitor cells after addition of appropriate cytokines chosen by the user .
pessina a et al. (2009) application of human cfu - mk assay to predict potential thrombocytotoxicity of drugs. toxicol in vitro 23 (1): 194 - 200
yasui k et al. (2003) differences between peripheral blood and cord blood in the kinetics of lineage - restricted hematopoietic cells: implications for delayed platelet recovery following cord blood transplantation. stem cells 21 (2): 143 - 151 pirson l et al. (2006) despite inhibition of hematopoietic progenitor cell growth in vitro, the tyrosine kinase inhibitor imatinib does not impair engraftment of human cd133 + cells into nod / scidbeta2mnull mice. stem cells 24 (7): 1814 - 1821
matsumura - takeda k et al. (2007) cd41 + / cd45 + cells without acetylcholinesterase activity are immature and a major megakaryocytic population in murine bone marrow. stem cells 25 (4): 862 - 870 boyer l et al. (2008) increased production of megakaryocytes near purity from cord blood cd34 + cells using a short two - phase culture system. j immunol methods 332 (1 - 2): 82 - 91 vodyanik m et al. (2006) leukosialin (cd43) defines hematopoietic progenitors in human embryonic stem cell differentiation cultures. blood 108 (6): 2095 - 2105821
stemcell technologies inc. is a global biotechnology company that develops , manufactures and sells products and provides services that support academic and industrial scientists . the company specializes in developing cell culture media , cell separation products , instruments and other reagents for use in stem cell , immunology , cancer , regenerative medicine and cellular therapy research . stemcell ’s research and development team often collaborates with academic and industrial partners to develop , produce and distribute products specific to a given research field . stemcell has helped several scientific technologies born in academic research settings to reach the global biotechnology market . stemcell is headquartered in vancouver , canada , and has offices in eight countries including the united states , united kingdom , germany , france , australia , singapore and china , as well as distributors in approximately 80 other countries . stemcell is the largest biotechnology company in canada , currently employing more than 800 people globally and offers a catalogue of more than 2,200 products . 
stemcell technologies inc. is a global biotechnology company that develops, manufactures and sells products and provides services that support academic and industrial scientists. the company specializes in developing cell culture media, cell separation products, instruments and other reagents for use in stem cell, immunology, cancer, regenerative medicine and cellular therapy research. stemcell ’s research and development team often collaborates with academic and industrial partners to develop, produce and distribute products specific to a given research field. stemcell has helped several scientific technologies born in academic research settings to reach the global biotechnology market. stemcell is headquartered in vancouver, canada, and has offices in eight countries including the united states, united kingdom, germany, france, australia, singapore and china, as well as distributors in approximately 80 other countries. stemcell is the largest biotechnology company in canada, currently employing more than 800 people globally and offers a catalogue of more than 2,200 products.
stemcell technologies inc. is a global biotechnology company that develops, manufactures and sells products and provides services that support academic and industrial scientists. the company specializes in developing cell culture media, cell separation products, instruments and other reagents for use in stem cell, immunology, cancer, regenerative medicine and cellular therapy research. stemcell ’s research and development team often collaborates with academic and industrial partners to develop, produce and distribute products specific to a given research field. stemcell has helped several scientific technologies born in academic research settings to reach the global biotechnology market. stemcell is headquartered in vancouver, canada, and has offices in eight countries including the united states, united kingdom, germany, france, australia, singapore and china, as well as distributors in approximately 80 other countries. stemcell is the largest biotechnology company in canada, currently employing more than 800 people globally and offers a catalogue of more than 2,200 products.